Nav: Home

Hidden immune cells cause lung transplant failure

June 14, 2017

CHICAGO --- Northwestern Medicine scientists have discovered that a subset of immune cells called nonclassical monocytes (NCMs), previously unknown to reside in the lungs, play a key role in driving primary graft dysfunction (PGD), the leading cause of death after lung transplantation.

The study, published June 14 in Science Translational Medicine, also demonstrates targeting these cells could lead to novel treatments for PGD, a complication that currently impacts more than half of transplant patients.

Dr. Ankit Bharat, an assistant professor of surgery at Northwestern University Feinberg School of Medicine and a Northwestern Medicine physician, was the principal investigator of the study.

"This is a widespread, lethal problem and the biggest reason why lung transplant patients experience both early death and long-term problems. So, if you can fix PGD, you can really fix a lot about transplantation," Bharat said. "Now we know what causes it, and we can develop a treatment for it."

PGD is a severe form of lung injury that develops when the recipient's neutrophils -- white blood cells -- are recruited into the transplanted lung, initiating the inflammatory cascade and causing tissue damage. While it has been understood that neutrophils were the main effector cells seen in PGD, the mechanisms that drive their influx into the lung were unknown. Further, targeting the patient's neutrophils was not considered to be a practical strategy for treatment, given that those same cells are critical for defending the body against pathogens.

In the current study, the scientists demonstrated that NCMs hidden in the donor lung are the culprit ultimately responsible for initiating the damaging inflow of neutrophils following transplantation of that lung.

Previously, it had been thought that all donor immune cells are eradicated when the lungs are flushed with a solution prior to transplantation. But the scientists discovered that NCMs -- a type of immune cell whose structure and function have only recently been described -- are actually retained in the blood vessels of the donor lung.

After identifying these cells in the lungs for the first time, the scientists further demonstrated their fundamental role in developing PGD: NCMs activate a pathway that produces a protein called CXCL2, which acts to attract the damaging neutrophils into the lung.

The findings suggest that targeting NCMs in the donor lungs could potentially prevent the development of PGD.

"This is a clinically-relevant finding because it would likely be easy to develop a drug that kills these cells at the time of transplant," said Bharat, also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "That's a big strength of our findings: because these are donor-derived cells, you could administer those drugs to the donor lungs before transplant and prevent any potential side effects to the recipient."

The NCMs also don't seem to play a role in a recipient's ability to fight infection, the scientists found, indicating that the cells could be eradicated without weakening the immune system.

The scientists now plan to investigate developing a drug that would eliminate NCMs during transplantation. Similar therapies have already been demonstrated in their animal models.

Separately, the research also seems to suggest that these monocytes may play a broader role in other forms of lung injury beyond transplantation, including acute respiratory distress syndrome. Those findings are forthcoming in future publications.

Bharat was initially driven to investigate primary graft dysfunction after a lung transplant patient of his developed the syndrome.

"We truly believe here that if a patient develops an unsolvable problem, it should be our commitment and duty to do everything we can to take that problem to our scientific laboratories, find a cure, and then bring it back to patients," Bharat said. "Hence, while we ensure that the patients receive the best technical expertise in the field of lung transplantation -- we also want to advance the field by finding cures for such lethal problems to really make a difference in patient outcomes."

Bharat and his collaborators followed a similar path two years ago when they identified the mechanism behind hyperammonemia syndrome, a fatal disorder which affects five percent of lung transplant recipients, after it affected one of their patients. The findings, also published in Science Translational Medicine, eventually led to a treatment for a deadly syndrome that had plagued the field of lung transplantation since its inception.

"For several years since it was first identified, recipients have been dying of hyperammonemia. And now with this discovery, everyone can be effectively treated," Bharat said. "I hope that, similarly, with primary graft dysfunction we can now develop a treatment for this lethal problem."

Dr. Zhikun Zheng, a former research fellow, and Dr. Stephen Chiu, a postdoctoral fellow in the Bharat laboratory, were the first authors of the study.

The scientists demonstrated the findings using a number of sophisticated methods, including a mouse transplant model with live high-resolution single cell imaging, immunoelectron microscopy, and transcriptomic profiling using RNA-sequencing.
The paper was also co-authored by Dr. Scott Budinger, Harris Perlman, Dr. Alexander Misharin, Farida Korobova and others.

Bharat, Budinger, Perlman and Misharin are also members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

The study was supported by National Institutes of Health (NIH) T32 DK077662 (Transplant Scientist Training Program and American Society for Transplant Surgery Resident Research Scholarship), NIH P01 AG049665, NIH P01 HL071643 (Department of the Army PR141319), and NIH HL125940 (Thoracic Surgery Foundation, American Lung Association and Society of University Surgeons.

More News at Northwestern Now

Northwestern University

Related Neutrophils Articles:

Creighton physicist's work unveils new ability of immune cells
Being able to quiet active neutrophils with a dual-beam laser could lead to new treatments for lung injury.
Immunology: How ancestry shapes our immune cells
A genetic variant that is particularly prevalent in people of African ancestry confers protection against malaria.
Lung study points to new therapies to treat critical illness
Scientists at the University of Edinburgh have pinpointed a chemical signal that worsens inflammation linked to a life-threatening lung condition.
Potential new treatment for kidney failure in cancer patients
Kidney dysfunction is a frequent complication affecting more than 50 percent of all cancer patients, and is directly linked to poor survival.
CNIC scientists discover how a decades-old drug reduces the size of a heart attack
The beta-blocker metoprolol can limit cardiac damage in patients having a heart attack.
Breakdown of neutrophil protein causes severe autoimmune disease of blood vessels
Osaka University researchers revealed that patients with a severe autoimmune disease that attacks the blood vessels lack the membrane form of a protein (SEMA4D) found in white blood cells.
Study shows how H. pylori causes white blood cells to morph
Veterans Affairs researchers and colleagues in Iowa showed in a lab study how neutrophils -- the most prevalent type of white blood cell -- undergo changes when infected by the common pathogen H. pylori.
White blood cell treatment could prevent leading cause of fetal death
Treating a type of white blood cell using hormones could improve the development of the placenta in women with pregnancy complications, according to early research led by Queen Mary University of London (QMUL) involving mice and human blood samples.
Research team discovers a pathogen's motility triggers immune response
Until now, a pathogen's ability to move through the body has been overlooked as a possible trigger of immune response, but new research from the University of Georgia College of Veterinary Medicine found that motility will indeed alarm the host and activate an immune response.
Mechanism revealed for side effects of drug used in hematopoietic stem cell harvesting
A team of Japanese researchers revealed the mechanism for side effects such as fever and bone pain caused by G-CSF, which is widely used for peripheral blood hematopoietic stem cell harvesting.

Related Neutrophils Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...